Reported cash
Cash and cash equivalents · Restricted cash and marketable securities excluded
Cash verified Nov 16, 2026
Price chart
What changed?
No verified development in tracked sources.
Upcoming catalysts
Next verified event · FDA target date
povetacicept · November 30, 2026
Announced Nov 2, 2026
Official announcementSource wording
•The BLA submission for accelerated approval of povetacicept in IgAN is under priority review by the U.S. FDA, with an assigned PDUFA target action date of November 30, 2026. The submission is supported by positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept in IgAN. If approved, povetacicept will become the first commercialized therapy in Vertex’s emerging nephrology franchise.
Clinical readout window
inaxaplin · interim analysis data · early 2027
Announced Nov 2, 2026 · Announced window
Official announcementSource wording
•Having completed enrollment in the interim analysis (IA) cohort of the AMPLITUDE pivotal study last year, Vertex has now completed full enrollment. Vertex remains on track to conduct the pre-planned IA for potential U.S. accelerated approval after the IA cohort reaches 48 weeks of treatment and to share data from the IA in early 2027. The FDA has granted Breakthrough Therapy designation to inaxaplin, and the European Medicines Agency (EMA) has granted PRIME designation.
Clinical readout window
povetacicept · gMG data · H1 2027
gMG
Phase 2
Announced Nov 2, 2026 · Announced window
Official announcementSource wording
•Vertex has completed enrollment in the placebo-controlled, Phase 2 dose-ranging proof-of-concept study evaluating povetacicept for the treatment of gMG. Vertex is on track to share results from the study in the first half of 2027.
Clinical readout window
suzetrigine · clinical data · mid 2027
diabetic peripheral neuropathy (DPN)
Phase 3
Announced Nov 2, 2026 · Announced window
Official announcementSource wording
•Vertex remains on track to complete enrollment in both Phase 3 studies of suzetrigine in diabetic peripheral neuropathy (DPN), a form of peripheral neuropathic pain (PNP), by the end of 2026 and to share results in mid-2027.
Clinical readout window
VX-993 · clinical data · mid 2027
DPN
Phase 2
Announced Nov 2, 2026 · Announced window
Official announcementSource wording
•Vertex is also on track to complete enrollment in a Phase 2 study of VX-993 in people with DPN by the end of 2026 and also to share results in mid-2027.
Drug pipeline
0 programs · 0 verified studies
No verified studies linked yet.
294 unverified sponsor matches remain unlinked.
Verified timeline
0 recordsNo verified developments in tracked sources.